Guardant Health, Inc.
NASDAQ:GHMedical - Diagnostics & Research
+$2.67 today
- Market cap
- $19.64B
- Beta
- 1.62
- P/E (TTM)
- -39.9
- EPS (TTM)
- -$3.30
Volume 1.50M
Average 2.21M
GH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Guardant Health, Inc.NASDAQ: GH
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $100.84M rose 12.1% year over year, ahead of the +7.6% change in trailing-twelve-month research & development. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at -0.9% a year.
Context
- Research & development amounted to 37.1% of revenue in FY2025, down 10.0 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +12.1% holds above the trailing-twelve-month pace of +7.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 364.19M USD
- Year-over-year change
- +4.7%
- 4-year CAGR
- +8.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 364.19M | +4.7% |
| FY2024 | 2024-12-31 | 347.75M | -5.3% |
| FY2023 | 2023-12-31 | 367.19M | -1.8% |
| FY2022 | 2022-12-31 | 373.81M | +42.0% |
| FY2021 | 2021-12-31 | 263.22M | — |
Research & Development vs competitors
How GH compares with its peers on the latest reported figures
- GH's LTM Sep 2026 research & development of $386.67M is the 2nd highest of the 10 companies compared; the peer median is $55.69M.
- Its year-over-year change of +7.6% is the 6th highest of 10, against a peer median of +9.5%.
- Research & development amounts to 30.2% of revenue for GH, versus a peer median of 15.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $787.38M | +56.9% | +25.4% | 29.1% | |
| LTM Sep 2026 | $386.67M | +7.6% | -0.9% | 30.2% | |
| LTM Jun 2026 | $190.99M | -15.8% | -15.9% | 115.6% | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $59.21M | +38.6% | — | 14.9% |
| LTM Mar 2026 | $55.69M | +11.9% | +23.1% | 17.4% | |
| LTM Mar 2026 | $53.69M | +5.8% | +4.9% | 15.8% | |
| LTM Mar 2026 | $52.16M | +6.9% | -8.2% | 80.9% | |
| LTM Jun 2026 | $38.17M | +9.5% | +6.9% | 5.0% | |
| LTM Mar 2026 | $12.42M | +19.5% | -2.9% | 12.9% | |
| Peer median (excluding GH) | $55.69M | +9.5% | +5.9% | 15.8% | |
Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 373.65M | 449.54M | 563.95M | 739.02M | 982.02M |
| Cost of Revenue | 122.91M | 156.33M | 227.05M | 289.8M | 349.01M |
| Gross Profit | 250.74M | 293.21M | 336.9M | 449.22M | 633.01M |
| Gross Margin | 67.1% | 65.2% | 59.7% | 60.8% | 64.5% |
| Research & Development | 263.22M | 373.81M | 367.19M | 347.75M | 364.19M |
| Selling, General & Admin | 398.52M | 463.78M | 451.03M | 545.06M | 706.07M |
| Operating Expenses | 661.74M | 837.59M | 901.62M | 892.81M | 1.07B |
| Depreciation & Amortization | 22.27M | 35.96M | 42.88M | 42.39M | 39.74M |
| EBITDA | (359.62M) | (614.91M) | (433.31M) | (390.12M) | (373.91M) |
| EBITDA Margin | -96.2% | -136.8% | -76.8% | -52.8% | -38.1% |
| Operating Income | (411M) | (544.38M) | (564.73M) | (443.59M) | (437.25M) |
| Operating Margin | -110.0% | -121.1% | -100.1% | -60.0% | -44.5% |
| Interest Income | 3.93M | 6.07M | 35.37M | 53.69M | 34.1M |
| Interest Expense | 2.58M | 2.58M | 2.58M | 2.58M | 3.9M |
| Other Income / Expenses | 26.53M | (109.07M) | 85.96M | 8.51M | 19.71M |
| Income Before Tax | (384.47M) | (653.45M) | (478.76M) | (435.09M) | (417.54M) |
| Pre-Tax Margin | -102.9% | -145.4% | -84.9% | -58.9% | -42.5% |
| Income Tax Expense | 300K | 1.14M | 685K | 1.28M | (1.26M) |
| Net Income | (405.67M) | (654.59M) | (479.45M) | (436.37M) | (416.28M) |
| Net Margin | -108.6% | -145.6% | -85.0% | -59.0% | -42.4% |
| EPS (Basic) | (4.00) | (6.41) | (4.28) | (3.56) | (3.32) |
| EPS (Diluted) | (4.00) | (6.41) | (4.28) | (3.56) | (3.32) |
| Weighted Avg Shares | 101.31M | 102.18M | 111.99M | 122.75M | 125.37M |
| Weighted Avg Shares (Diluted) | 101.31M | 102.18M | 111.99M | 122.75M | 125.37M |
Guardant Health, Inc.
NASDAQ:GH
Intrinsic Alpha fair value
Locked
Current Price
$145.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.